Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tazarotene · 1 trial · 2 indications
General overall safety and tolerability of oral GRI-0621 as compared to placebo will be assessed by evaluating the following safety parameters: * Adverse events (occurrence and type) * Clinical Laboratory Measurements (normal/abnormal) * Vital signs (normal/abnormal)
| Arm | Type | Description |
|---|---|---|
| GRI-0621 | EXPERIMENTAL | GRI-0621 (tazarotene) 4.5mg, administered orally once daily (QD) |
| Placebo | EXPERIMENTAL | Placebo 4.5mg, administered orally once daily (QD) |
| Name | Type | Description |
|---|---|---|
| Tazarotene (GRI-0621) | DRUG | Oral 4.5mg soft gel capsule |
| Placebo | DRUG | Oral 4.5mg soft gel capsule |
Inclusion Criteria: 1. Male or female subjects 40 through 85 years of age, inclusive. 2. Confirmed diagnosis of IPF with clinical features consistent with the current clinical practice guidelines for IPF. 3. FVC \> 50% predicted value within 4 weeks of Screening. 4. FEV1/FVC ratio \> 0.65 within 4 ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 2 | PHASE3 | BMS-986278 |
| United Therapeutics Corporation | UTHR | 2 | PHASE3 | Treprostinil |
| PureTech Health PLC Sponsored ADR | PRTC | 2 | PHASE3 | Deupirfenidone, Pirfenidone |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | ABBV-142 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE2 | Axatilimab |
| Contineum Therapeutics, Inc. Class A | CTNM | 1 | PHASE2 | PIPE-791 Dose A, PIPE-791 Dose B |
| Rein Therapeutics, Inc | RNTX | 1 | PHASE2 | LTI-03 |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | HEC585, Pirfenidone |
| Cumberland Pharmaceuticals Inc. | CPIX | 1 | PHASE2 | Ifetroban |
| Avalyn Pharma Inc | AVLN | 3 | PHASE2 | AP01 |
| Trevi Therapeutics, Inc. | TRVI | 1 | PHASE1 | NAL |